Ardelyx (ARDX)

• Market cap: $1.24B
• 1 day: -1.57%
• 5 days: -1.96%
• 1 month: -21.35%
• 3 months: -15.94%
• 6 months: -37.3%
• Year to date: -18.54%
• 1 year: 13.35%
• 5 years: 159.59%
• 10 years: -52.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 489